Biomm

Biomm R&D Expenses

The Research & Development Expenses of Biomm (BIOM3.SA) as of Nov 11, 2026 is 4.46 M BRL. In the previous year, Research & Development Expenses was 4.38 M BRL — a change of 1.83% (higher).

R&D Expenses

4.46 MBRL

YoY

1.83%

Last updated:

Research & Development Expenses of Biomm is 2020 4.46 M BRL. Research & Development Expenses of Biomm was 2019 4.38 M BRL. It decreases by 1.83% higher compared to the previous year.

The Biomm R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2019
4.38 M BRL
Jan 1, 2020
4.46 M BRL
The Biomm R&D Expenses history
YEARR&D ExpensesYoY
4.46 MBRL+1.83%
4.38 MBRL—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomm stock

Research & Development Expenses of Biomm is 4.46 M BRL in 2020.

Research & Development Expenses of Biomm changed from 4.38 M BRL to 4.46 M BRL, representing a 1.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Biomm since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's BRL is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Biomm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Biomm

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Biomm